Fever and neutropenia clinical practice guidelines.

Alison G. Freifeld, Lindsey Robert Baden, Arthur E. Brown, Linda S. Elting, Michael Gelfand, John N. Greene, James I. Ito, Earl King, Guido Marcucci, Jose G. Montoya, Ashley Morris, Gary Noskin, Ken Rolston, Anne F. Schott, Brahm Segal

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Significant progress has been made in managing fever and neutropenia in patients with cancer. Although initial empiric antimicrobial treatment remains the foundation of therapy for such patients, improved diagnostic modalities, models of risk assessment, and an understanding of the various clinical situations in which infections occur have required that treatment approaches and options evolve. The development of broad-spectrum antibiotics with decreased toxicity has improved patient outcomes. Nevertheless, the increasing prevalence of antibiotic-resistant pathogens has challenged the clinician to use antimicrobial therapy wisely. Infection control should not rely exclusively on antimicrobial prophylaxis but, rather, should continue to incorporate standard infection control measures and demand careful handwashing by all health care professionals who come into contact with immunocompromised patients. Invasive fungal pathogens have increased and remain a major concern. Diagnostic and therapeutic modalities for fungal infections remain limited, but careful clinical investigation of new approaches will be needed to define the proper use of these probably expensive new therapeutic additions.

Original languageEnglish (US)
Pages (from-to)390-432
Number of pages43
JournalJournal of the National Comprehensive Cancer Network : JNCCN
Volume2
Issue number5
StatePublished - Sep 1 2004

Fingerprint

Neutropenia
Practice Guidelines
Fever
Infection Control
Therapeutics
Anti-Bacterial Agents
Hand Disinfection
Mycoses
Immunocompromised Host
Delivery of Health Care
Infection
Neoplasms

ASJC Scopus subject areas

  • Oncology

Cite this

Freifeld, A. G., Baden, L. R., Brown, A. E., Elting, L. S., Gelfand, M., Greene, J. N., ... Segal, B. (2004). Fever and neutropenia clinical practice guidelines. Journal of the National Comprehensive Cancer Network : JNCCN, 2(5), 390-432.

Fever and neutropenia clinical practice guidelines. / Freifeld, Alison G.; Baden, Lindsey Robert; Brown, Arthur E.; Elting, Linda S.; Gelfand, Michael; Greene, John N.; Ito, James I.; King, Earl; Marcucci, Guido; Montoya, Jose G.; Morris, Ashley; Noskin, Gary; Rolston, Ken; Schott, Anne F.; Segal, Brahm.

In: Journal of the National Comprehensive Cancer Network : JNCCN, Vol. 2, No. 5, 01.09.2004, p. 390-432.

Research output: Contribution to journalArticle

Freifeld, AG, Baden, LR, Brown, AE, Elting, LS, Gelfand, M, Greene, JN, Ito, JI, King, E, Marcucci, G, Montoya, JG, Morris, A, Noskin, G, Rolston, K, Schott, AF & Segal, B 2004, 'Fever and neutropenia clinical practice guidelines.', Journal of the National Comprehensive Cancer Network : JNCCN, vol. 2, no. 5, pp. 390-432.
Freifeld AG, Baden LR, Brown AE, Elting LS, Gelfand M, Greene JN et al. Fever and neutropenia clinical practice guidelines. Journal of the National Comprehensive Cancer Network : JNCCN. 2004 Sep 1;2(5):390-432.
Freifeld, Alison G. ; Baden, Lindsey Robert ; Brown, Arthur E. ; Elting, Linda S. ; Gelfand, Michael ; Greene, John N. ; Ito, James I. ; King, Earl ; Marcucci, Guido ; Montoya, Jose G. ; Morris, Ashley ; Noskin, Gary ; Rolston, Ken ; Schott, Anne F. ; Segal, Brahm. / Fever and neutropenia clinical practice guidelines. In: Journal of the National Comprehensive Cancer Network : JNCCN. 2004 ; Vol. 2, No. 5. pp. 390-432.
@article{b4f9104814da46f5b1074bd0d5f472fb,
title = "Fever and neutropenia clinical practice guidelines.",
abstract = "Significant progress has been made in managing fever and neutropenia in patients with cancer. Although initial empiric antimicrobial treatment remains the foundation of therapy for such patients, improved diagnostic modalities, models of risk assessment, and an understanding of the various clinical situations in which infections occur have required that treatment approaches and options evolve. The development of broad-spectrum antibiotics with decreased toxicity has improved patient outcomes. Nevertheless, the increasing prevalence of antibiotic-resistant pathogens has challenged the clinician to use antimicrobial therapy wisely. Infection control should not rely exclusively on antimicrobial prophylaxis but, rather, should continue to incorporate standard infection control measures and demand careful handwashing by all health care professionals who come into contact with immunocompromised patients. Invasive fungal pathogens have increased and remain a major concern. Diagnostic and therapeutic modalities for fungal infections remain limited, but careful clinical investigation of new approaches will be needed to define the proper use of these probably expensive new therapeutic additions.",
author = "Freifeld, {Alison G.} and Baden, {Lindsey Robert} and Brown, {Arthur E.} and Elting, {Linda S.} and Michael Gelfand and Greene, {John N.} and Ito, {James I.} and Earl King and Guido Marcucci and Montoya, {Jose G.} and Ashley Morris and Gary Noskin and Ken Rolston and Schott, {Anne F.} and Brahm Segal",
year = "2004",
month = "9",
day = "1",
language = "English (US)",
volume = "2",
pages = "390--432",
journal = "JNCCN Journal of the National Comprehensive Cancer Network",
issn = "1540-1405",
publisher = "Cold Spring Publishing LLC",
number = "5",

}

TY - JOUR

T1 - Fever and neutropenia clinical practice guidelines.

AU - Freifeld, Alison G.

AU - Baden, Lindsey Robert

AU - Brown, Arthur E.

AU - Elting, Linda S.

AU - Gelfand, Michael

AU - Greene, John N.

AU - Ito, James I.

AU - King, Earl

AU - Marcucci, Guido

AU - Montoya, Jose G.

AU - Morris, Ashley

AU - Noskin, Gary

AU - Rolston, Ken

AU - Schott, Anne F.

AU - Segal, Brahm

PY - 2004/9/1

Y1 - 2004/9/1

N2 - Significant progress has been made in managing fever and neutropenia in patients with cancer. Although initial empiric antimicrobial treatment remains the foundation of therapy for such patients, improved diagnostic modalities, models of risk assessment, and an understanding of the various clinical situations in which infections occur have required that treatment approaches and options evolve. The development of broad-spectrum antibiotics with decreased toxicity has improved patient outcomes. Nevertheless, the increasing prevalence of antibiotic-resistant pathogens has challenged the clinician to use antimicrobial therapy wisely. Infection control should not rely exclusively on antimicrobial prophylaxis but, rather, should continue to incorporate standard infection control measures and demand careful handwashing by all health care professionals who come into contact with immunocompromised patients. Invasive fungal pathogens have increased and remain a major concern. Diagnostic and therapeutic modalities for fungal infections remain limited, but careful clinical investigation of new approaches will be needed to define the proper use of these probably expensive new therapeutic additions.

AB - Significant progress has been made in managing fever and neutropenia in patients with cancer. Although initial empiric antimicrobial treatment remains the foundation of therapy for such patients, improved diagnostic modalities, models of risk assessment, and an understanding of the various clinical situations in which infections occur have required that treatment approaches and options evolve. The development of broad-spectrum antibiotics with decreased toxicity has improved patient outcomes. Nevertheless, the increasing prevalence of antibiotic-resistant pathogens has challenged the clinician to use antimicrobial therapy wisely. Infection control should not rely exclusively on antimicrobial prophylaxis but, rather, should continue to incorporate standard infection control measures and demand careful handwashing by all health care professionals who come into contact with immunocompromised patients. Invasive fungal pathogens have increased and remain a major concern. Diagnostic and therapeutic modalities for fungal infections remain limited, but careful clinical investigation of new approaches will be needed to define the proper use of these probably expensive new therapeutic additions.

UR - http://www.scopus.com/inward/record.url?scp=25144512287&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=25144512287&partnerID=8YFLogxK

M3 - Article

C2 - 19780251

AN - SCOPUS:25144512287

VL - 2

SP - 390

EP - 432

JO - JNCCN Journal of the National Comprehensive Cancer Network

JF - JNCCN Journal of the National Comprehensive Cancer Network

SN - 1540-1405

IS - 5

ER -